Certior Health (“Certior”) is pleased to announce that it has partnered with Datar Cancer Genetics, a leading cancer research company, focussed on evidence-based testing procedures both in the field of therapy management and cancer screening. The initial test being launched is Trucheck™, an innovative cancer screening test that requires a safe, simple and quick blood draw, allowing for early detection of cancer by detecting Circulating Tumour Cells (CTCs). Trucheck™ Intelli can distinguish 70 types of cancers which account for 81% of all cancer cases and 84% of all cancer-related deaths in Ireland. Certior Health is now offering Trucheck™ testing in Ireland at their clinic in Blanchardstown, Dublin.
A recent survey of 1,034 Irish adults revealed that 88% of participants were aware of blood-based cancer screening and expressed a strong interest in learning more about this innovative approach.1 The survey, commissioned by Certior Health, aimed to assess patient needs, awareness, and understanding of cancer screening, while identifying any concerns around accessing such tests.
The research revealed that 41% of survey participants have had immediate experience with cancer, either themselves or through an immediate family member (parent, child or sibling). Notably, women exhibited a greater understanding and uptake of cancer screening compared to men. However, just 37% of women aged 45-54 are aware of when BreastCheck screening should start. Of all those surveyed, most expressed a strong desire to learn more about their health, whilst 3% said they would prefer not to know if they had cancer. 77% said they would be willing to pay for private screening.
Dr Vineet Datta, Executive Director at Datar Cancer Genetics, said: “We are delighted to partner with Certior. This collaboration will provide advanced cancer genomics to the patient community, and we will work closely with Certior’s medical team to support better-informed clinical decision-making. Trucheck™ is a CE-certified cancer screening solution offered for single and multi-organ cancer screening. We believe the solution will encourage more men and women to participate in cancer screening for a safer future. “
Dr Nick Flynn, Chief Medical Officer for Certior Health emphasised the importance of cancer screening, stating, “Cancer is the leading cause of death in Ireland, responsible for approximately 30% of all deaths each year.2 By enabling early detection and intervention, Trucheck™ empowers individuals to take charge of their health.
Timely screening not only increases the chances of successful treatment but also offers peace of mind and reassurance to those at risk. It is crucial that we continue to prioritise and expand access to innovative screening options to enhance cancer prevention and ultimately improve health outcomes for the Irish population.”
Maggie Malone, CEO of Certior Health, shared her personal experience with breast cancer in 2017 and highlighted the significance of early detection. She stated, “Each year, an estimated 44,000 people are diagnosed with cancer in Ireland.3 Trucheck™ provides a safe and reliable way for individuals to get screened.
Trucheck™️ can detect over 70 types of cancer and is intended to complement routine cancer screenings for early detection. Additionally, this solution can also detect various other cancers, not currently screened for regularly such as ovarian cancer, pancreatic cancer and lung cancer. TruCheck™️ through its innovative and novel process of utilising CTCs to identify cancers in both early and advanced stages, has been validation in more than 40,000 individuals.
Datar stands out due to their advanced technology and unique approach to blood-based cancer screening. We leverage cutting-edge molecular and genetic analysis techniques to detect specific biomarkers associated with different types of cancer.
Our tests are highly sensitive and specific, providing an accuracy rate of 96.8%. We are keen to make our tests accessible and affordable, ensuring that more people can benefit from early cancer detection. To this end, we are currently in talks to be partially reimbursed via private health insurers, as well as several large employers.”
Currently, Trucheck™cancer screening is available at Certior Health’s Centre in Blanchardstown, Dublin. Certior is committed to expanding access to Trucheck™ across Ireland, ensuring that more individuals can benefit from this groundbreaking screening technology.
Patients can self-refer for screening. The test is suitable for adults over the age of 40 who are asymptomatic and have a risk of cancer. For more information about Trucheck™, please visit certior.com.
